Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 13/20 | 0.44 |
| ▸ | JAK2 | O60674 | 7/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298090 | 0.91 | LRRK2 (0.48) | LRRK2JAK1JAK2TRPV1BCDIN3D | |
| SCHEMBL12103610 | 0.86 | LRRK2 (0.46) | LRRK2JAK1JAK2TRPV1TYK2 | |
| Hydrochloric Acid SCHEMBL1298178 | 0.85 | LRRK2 (0.45) | LRRK2JAK1JAK2TRPV1TYK2 | |
| SCHEMBL1298221 | 0.85 | LRRK2 (0.45) | LRRK2JAK1JAK2TRPV1BCDIN3D | |
| SCHEMBL1299254 | 0.85 | LRRK2 (0.47) | LRRK2JAK1JAK2TYK2SLC2A1 | |
| SCHEMBL1299256 | 0.85 | LRRK2 (0.47) | LRRK2JAK1JAK2TYK2SLC2A1 | |
| SCHEMBL1298486 | 0.81 | LRRK2 (0.47) | LRRK2JAK1JAK2TYK2 | |
| SCHEMBL1299003 | 0.78 | LRRK2 (0.49) | LRRK2JAK1JAK2TRPV1SLC2A1 | |
| SCHEMBL1299005 | 0.78 | LRRK2 (0.49) | LRRK2JAK1JAK2TRPV1SLC2A1 | |
| SCHEMBL1298250 | 0.77 | JAK1 (0.48) | LRRK2JAK1JAK2BCDIN3DTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404677-B2 | Kinase inhibitors | GENOSCO (US) | 2013-03-26 | — | — | US | claimed |
| US-20110269739-A1 | KINASE INHIBITORS | OSCOTEC, INC. (KR) | 2011-11-03 | — | — | US | claimed |
| US-8404677-B2 | Kinase inhibitors | GENOSCO (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404677-B2 | Kinase inhibitors | GENOSCO (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404677-B2 | Kinase inhibitors | GENOSCO (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110269739-A1 | KINASE INHIBITORS | OSCOTEC, INC. (KR) | 2011-11-03 | — | — | US | disclosed |
| US-20110269739-A1 | KINASE INHIBITORS | OSCOTEC, INC. (KR) | 2011-11-03 | — | — | US | disclosed |
| US-20110269739-A1 | KINASE INHIBITORS | OSCOTEC, INC. (KR) | 2011-11-03 | — | — | US | disclosed |
| WO-2011053861-A1 | KINASE INHIBITORS | GENOSCO (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269739-A1 | KINASE INHIBITORS | JAK1, LCK, MAP3K20 | LRRK2 436/4885JAK1 1/4885JAK2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.